When we looked at the pre-treatment creatinine data, we found that African Americans were more likely to have abnormal results and white patients were more likely to have normal results–these differences were statistically significant, said Abby Statler, PhD, MPH, MA, research associate at Cleveland Clinic.
When we looked at the pre-treatment creatinine data, we found that African Americans were more likely to have abnormal results and white patients were more likely to have normal results—these differences were statistically significant, said Abby Statler, PhD, MPH, MA, research associate at Cleveland Clinic.
Transcript
What did you find in your study of African American patients with AML with abnormal kidney tests?
So, when we looked at the pre-treatment creatinine data, and creatinine measures your kidney function, we found that African Americans were more likely to have abnormal results and white patients are more likely to have normal results—these differences were statistically significant. Additionally, when we looked at creatinine clearance data, again, a measure for kidney function, African Americans again had worse results than the white patient population. Again, suggesting that their kidney function is indeed worse than the white patient population. So, across the full cohort, 56% of the patients had some sort of renal dysfunction; but this proportion was higher among African Americans–63% of which had some sort of renal function abnormality that could have potentially excluded them from a clinical trial, but our outcomes suggest that minor renal dysfunction is not associated with clinical outcomes. Therefore, this might not be a reason alone to be excluding patients from clinical trials.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More